Research graph
References from Hepatitis B Reactivation in People With HIV After Switching to a 2-Drug Anti-HBV Sparing Regimen. Local targets link to admitted publications; unresolved targets remain external evidence.
Update of the statements on biology and clinical impact of occult hepatitis B virus infection
10.1016/j.jhep.2019.03.034 · 2019 · External reference
Very low prevalence and no clinical significance of occult hepatitis B in a cohort of HIV-infected patients with isolated anti-HBc seropositivity: the BHOI study
10.1310/hct0905-337 · 2008 · External reference
Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV cohort study
10.1007/bf01584356 · 1998 · External reference
Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients
10.1089/aid.2005.21.922 · 2005 · External reference
Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women
10.1086/520989 · 2007 · External reference
Incidence of transaminitis among HIV-infected patients with occult hepatitis B
10.1016/j.jcv.2008.03.030 · 2008 · External reference
Longitudinal evaluation of occult hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption
10.1007/s15010-011-0093-9 · 2011 · External reference
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIV
10.1016/s2352-3018(19)30342-x · 2020 · External reference
Droplet digital PCR assay as an innovative and promising highly sensitive assay to unveil residual and cryptic HBV replication in peripheral compartment
10.1016/j.ymeth.2021.05.011 · 2022 · External reference
In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to tenofovir-sparing therapy
2022 · External reference
Long-term TDF-inclusive ART and progressive rates of HBsAg loss in HIV-HBV coinfection—lessons for functional HBV cure?
10.1097/qai.0000000000002386 · 2020 · External reference
Hepatitis B infection or reactivation after switch to 2-drug antiretroviral therapy: a case series, literature review, and management discussion
10.1097/qai.0000000000003239 · 2023 · External reference
Hepatitis B reactivation in persons with HIV with positive hepatitis B core antibody after switching to antiretroviral therapy without hepatitis B activity
10.1093/ofid/ofad500.057 · 2023 · External reference
Hepatitis B virus reactivation after switch to cabotegravir/rilpivirine in patient with low hepatitis B surface antibody
10.3201/eid3008.240019 · 2024 · External reference
